Silver Book Fact

According to the Pharmaceutical Research and Manufacturers of America, one of the most promising medicines in development uses normal human cells to enhance brain levels of dopamine, the neurotransmitter deficient in Parkinson’s disease.

2006 Report: Medicines in development for neurological disorders. http://www.phrma.org/files/Neurologic_2006.pdf. Published 2006

Reference

Title
2006 Report: Medicines in development for neurological disorders
Publisher
PhRMA
Publication Date
Published 2006
Authors
PhRMA
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Slowing the Progress of Parkinson’s Disease Would Save Money
     
  • The U.S. Food and Drug Administration has approved 5 drugs that have proven to temporarily slow the worsening of Alzheimer’s disease symptoms for an average of 6 – 12 months…  
  • Research breakthroughs that slow the onset and progression of Alzheimer’s disease could achieve annual Medicare savings of $51 billion by 2015, $126 billion by 2025, and $444 billion by 2050.  
  • Early Gene Therapy Studies Show Promise for Parkinson’s Disease
     
  • It is imperative to weigh costs of implementing new technologies for predicting onset of Alzheimer’s disease through biomarkers and delaying onset earlier against the potential benefits of improving health. Overall…